AC Immune and Lilly Amend Tau License and Collaboration Agreement for Alzheimer's Disease Treatment

AC Immune has amended its license and collaboration agreement with Lilly to continue researching and developing Tau aggregation inhibitor small molecules for Alzheimer's disease and other neurodegenerative diseases. The agreement covers new lead Tau Morphomer candidates and potential back-up compounds. AC Immune will receive a CHF10 million upfront payment and is eligible for further development, regulatory, and commercial milestones of over CHF1.7 billion. Investigational New Drug (IND)-enabling studies are set to commence in H1 2026.